1631 related articles for article (PubMed ID: 17852414)
1. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
2. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R
Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
[TBL] [Abstract][Full Text] [Related]
3. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
4. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
[TBL] [Abstract][Full Text] [Related]
5. [Exploration of the classification of polycystic ovarian syndrome].
Lin JF; Li X; Zhu MW
Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
[TBL] [Abstract][Full Text] [Related]
6. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.
Fenkci SM; Fenkci V; Oztekin O; Rota S; Karagenc N
Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560
[TBL] [Abstract][Full Text] [Related]
7. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
Ortega-González C; Cardoza L; Coutiño B; Hidalgo R; Arteaga-Troncoso G; Parra A
J Endocrinol; 2005 Jan; 184(1):233-9. PubMed ID: 15642799
[TBL] [Abstract][Full Text] [Related]
8. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Kazerooni T; Dehghan-Kooshkghazi M
Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
[TBL] [Abstract][Full Text] [Related]
9. [Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases].
Song J; Shen H; Li J; Huang Z; Zhang Y
Zhonghua Fu Chan Ke Za Zhi; 2002 Feb; 37(2):86-9. PubMed ID: 11953071
[TBL] [Abstract][Full Text] [Related]
10. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study.
Kilicdag EB; Bagis T; Zeyneloglu HB; Tarim E; Aslan E; Haydardedeoglu B; Erkanli S
Hum Reprod; 2005 Apr; 20(4):894-9. PubMed ID: 15618250
[TBL] [Abstract][Full Text] [Related]
11. Increased follistatin levels after oral contraceptive treatment in obese and non-obese women with polycystic ovary syndrome.
Chen MJ; Yang WS; Chen HF; Kuo JJ; Ho HN; Yang YS; Chen SU
Hum Reprod; 2010 Mar; 25(3):779-85. PubMed ID: 20093255
[TBL] [Abstract][Full Text] [Related]
12. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
Yilmaz M; Bukan N; Ayvaz G; Karakoç A; Törüner F; Cakir N; Arslan M
Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091
[TBL] [Abstract][Full Text] [Related]
13. Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome.
Baranowska B; Radzikowska M; Wasilewska-Dziubińska E; Kapliński A; Roguski K; Płonowski A
Gynecol Endocrinol; 1999 Oct; 13(5):344-51. PubMed ID: 10599552
[TBL] [Abstract][Full Text] [Related]
14. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome.
Loverro G; Lorusso F; De Pergola G; Nicolardi V; Mei L; Selvaggi L
Gynecol Endocrinol; 2002 Jun; 16(3):217-24. PubMed ID: 12192894
[TBL] [Abstract][Full Text] [Related]
15. [Association of monocyte chemoattractant protein-1 and the clinical characteristics of polycystic ovary syndrome: analysis of 65 cases].
Hu WH; Qiao J; Li MZ
Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(11):721-4. PubMed ID: 17565837
[TBL] [Abstract][Full Text] [Related]
16. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
Hassa H; Tanir HM; Yildiz Z
Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
[TBL] [Abstract][Full Text] [Related]
17. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
[TBL] [Abstract][Full Text] [Related]
18. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome.
Kriplani A; Agarwal N
J Reprod Med; 2004 May; 49(5):361-7. PubMed ID: 15214709
[TBL] [Abstract][Full Text] [Related]
19. [Interrelationship of abnormal family history in the first degree relatives and clinical phenotype of patients with polycystic ovary syndrome].
Wang Y; Mao WW; Chen YJ; Li MZ; Qiao J; Wang LN
Zhonghua Fu Chan Ke Za Zhi; 2007 Nov; 42(11):756-60. PubMed ID: 18307903
[TBL] [Abstract][Full Text] [Related]
20. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial.
Chou KH; von Eye Corleta H; Capp E; Spritzer PM
Horm Metab Res; 2003 Feb; 35(2):86-91. PubMed ID: 12734787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
